Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kosmos shares fall on lower output, higher cost guidance

(Sharecast News) - UK-listed shares of American upstream oil company Kosmos dipped on Monday after the firm swung to a loss in the second quarter, as it forecasted lower production and higher costs than initially estimated. The Dallas-headquartered company announced that it was cutting its full-year production gudiance to 65,000-70,000 barrels of oil equivalent per day (boepd), down from the 70,000-80,000 boepd range announced in May.

Kosmos reported a net loss of $87.7m over the three months to 30 June, compared with a $59.8m profit the year before, total revenues fell to $393.5m from $450.9m.

Net production was 63,500 boe per day, lower than the 66,000-72,000 guidance range given in May.

Operating costs per boe, at $36.49, were well above company guidance of $25-27, reflecting lower production than expected, and were higher than the first quarter. As a result,. Kosmos has hiked its full-year opex guidance to $22-24 per boe, up from $18-20 previously.

Nevertheless, net capital expenditure for the quarter was $86m, below guidance due to lower spend in Mauritania and Senegal and in the Gulf of Mexico. Looking forward, the company cut its full-year capex target to $350m from $400m.

"We set out this year with three clear priorities: Increase production, reduce costs and enhance the resilience of the balance sheet. During the period we have continued to make good progress across all three areas," said chair and chief executive Andrew Inglis.

"With production rising, costs falling and balance sheet resilience improving, we look forward to delivering long-term value for our shareholders through the second half of the year and beyond."

The stock was down 4% at 145p by 0856 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.